Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (LIVN) is a global leader in medical technology innovation, specializing in life-supporting cardiopulmonary solutions and neuromodulation therapies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Track all official LivaNova press releases, earnings reports, and product development announcements in one centralized resource. Our curated news feed covers critical developments including FDA clearances, international expansion efforts, and partnerships shaping the future of cardiac surgery and neurological treatment technologies.
Key updates feature progress in extracorporeal circulation systems, enhancements to vagus nerve stimulation therapies, and sustainability initiatives across global manufacturing operations. The platform serves as a vital tool for monitoring how LivaNova’s innovations in heart-lung machines and depression treatment devices impact both patient outcomes and shareholder value.
Bookmark this page for immediate access to verified information about LIVN’s market position, intellectual property developments, and leadership changes. Stay informed about the medical technology pioneer driving advancements in critical care through its merged heritage of European and American engineering excellence.
LivaNova PLC (NASDAQ:LIVN), a leading medical technology company, announces its CEO, Damien McDonald, will present at two significant healthcare conferences: the Stifel 2021 Virtual Healthcare Conference on November 17 at 10 a.m. Eastern and the Jefferies 2021 London Healthcare Conference on November 18 at 3 a.m. Eastern. Both presentations will be accessible via webcasts on LivaNova’s website, with replays available for 90 days. LivaNova, headquartered in London, employs around 3,000 people and operates in over 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced a virtual Investor Day on December 7 from 8 a.m. to 12 p.m. CT. Executive leadership will present the long-range business plan aimed at maximizing growth and shareholder value. Additionally, the event will include overviews of the company’s franchises and strategic pipeline initiatives, with opportunities for Q&A sessions. Interested attendees can register via the LivaNova website. Following the event, a replay and presentation materials will be available online for one year.
LivaNova PLC (NASDAQ: LIVN) reported a 5.5% increase in third-quarter 2021 sales, reaching $253.2 million. Excluding the divested Heart Valves business, sales grew by 15.7%. Adjusted diluted EPS was $0.68, up from $0.38 in Q3 2020. The company raised 2021 guidance, projecting 8-11% net sales growth and adjusted EPS of $2.00 to $2.10. Operating income rose significantly to $17.9 million, with adjusted operating income at $47.9 million, a 49.1% increase. LivaNova also improved its cash flow and financial flexibility through an equity offering, retiring a $450 million term loan.
LivaNova PLC (NASDAQ:LIVN) will host a conference call on
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will speak at the Baird 2021 Global Healthcare Conference on September 15, 2021, at 9:40 a.m. ET. The presentation will be available via live webcast on the LivaNova website. Participants are encouraged to log in 10 minutes early. A replay will be available for 30 days post-event. LivaNova, headquartered in London, is dedicated to improving patient outcomes with innovative medical technologies, employing around 3,000 staff globally.
LivaNova PLC (NASDAQ:LIVN) has announced the early retirement of its $450 million senior secured term loan, repaying the principal along with a $35.6 million make-whole premium. This repayment reduces interest expenses by approximately $39 million annually. Funding came from a recent equity offering and cash reserves. Additionally, LivaNova executed a $125 million revolving credit facility with Goldman Sachs for general corporate purposes. For 2021, the company anticipates adjusted diluted earnings per share between $1.75 to $2.05 and adjusted free cash flow between $50 to $70 million.
LivaNova PLC (NASDAQ:LIVN) has priced an underwritten offering of 3,636,364 ordinary shares at $82.50 each, with a potential additional 545,454 shares. The net proceeds are projected to be about $280.1 million, aiming to partially repay a $450 million senior secured term loan. This offering is set to close on August 6, 2021, and is backed by an effective shelf registration statement. Goldman Sachs, Barclays, and UBS are the joint bookrunners, with shares available solely to qualified investors.
LivaNova PLC (NASDAQ:LIVN) has announced an underwritten offering of $300 million of ordinary shares, with an option for underwriters to purchase an additional 15%. Proceeds will be used to help repay a $450 million senior secured term loan, which incurred $9.7 million in interest expenses in Q2 2021. The offering is conducted under an effective shelf registration statement with the SEC. Joint bookrunners include Goldman Sachs, Barclays, and UBS.
LivaNova PLC (NASDAQ: LIVN) reported a strong performance for Q2 2021, with worldwide sales increasing 45.2% to $264.5 million. Excluding the divested Heart Valves business, sales rose 51.6% to $249.8 million. Neuromodulation sales surged 102.4%, reflecting a recovery in procedure volumes. However, the company posted a GAAP loss per share of $1.13. LivaNova has updated its 2021 guidance, anticipating net sales growth of 5-10% and adjusted earnings per share of $1.60-$1.90. Alex Shvartsburg has been appointed CFO, effective August 1, bringing 25 years of industry experience.
LivaNova PLC (NASDAQ:LIVN) will host a conference call to discuss its second quarter 2021 results on July 28, 2021, at 1 p.m. London time (8 a.m. EDT). The results will be released prior to the call. A live audiocast will be accessible on the company’s website. Participants are encouraged to log on 10 minutes early for setup. To join by phone, dial 844-558-0159 (U.S./Canada) or 236-714-3182 (international) with conference ID 3308297. Replays will be available for 90 days.
